Please see the attached notifications of trade for information regarding the subscription rights received by primary insiders and their close associates in the Rights Issue.
This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA gene therapies and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform for genetic medicine. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary
In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in
https://news.cision.com/circio/r/circio-holding-asa---receipt-of-subscription-rights-in-the-rights-issue-by-primary-insiders-and-thei,c4005267
https://mb.cision.com/Public/17093/4005267/aa1e49bea6e7f483.pdf
(c) 2024 Cision. All rights reserved., source